Health Research Methods, Evidence, and Impact


Deborah Marshall

BSc (Toronto), MHSA (Alberta), PhD (North Carolina)

Associate Professor (Part-time), Department of Health Research Methods, Evidence, and Impact

Canada Research Chair, Health Systems and Services Research

904.522.1155 x 34917
905.528.7386
marshd@mcmaster.ca

Centre for Evaluation of Medicines
105 Main St. East Level 1
Hamilton , ON
L8P 1H1

 

Academic Interests

Dr. Marshall's research and academic interests include: health technology assessment of new medical devices, drugs, and diagnostics; economic evaluation and cost-effectiveness analysis of health care programmes,  health systems modeling; methods for the measurement of patient preferences (using discrete choice experiments) particularly for screening and diagnostic technologies. Her areas of focus are in musculoskeletal disease and cancer. She is the Lead for the Economics Project in the TRANSPERS (Translational and Policy Research in Personalized Medicine in Cancer) Centre funded by the US National Institutes of Health. 

Selected Publications

  1. Marshall DA, McGregor E, Currie G.  Measuring preferences for colorectal cancer (CRC) screening – What are the implications for moving forward?  The Patient, Accepted for publication, October 2009
  2. Bridges JFP, Hauber B, Marshall DA, Lloyd A, Prosser LA, Regier DA, Johnson FR, Mauskopf J. A checklist for conjoint analysis applications in health: report of the ISPOR conjoint analysis good research practices taskforce. Value in Health 2009 (In press).
  3. McCarron E, Tarride JE, Marshall DA, Pullenayegum E, Goeree R. Handling Uncertainty in Economic Evaluations of Patient Level Data: A Review of the Use of Bayesian Methods.  International Journal of Health Technology Assessment, Accepted for publication, August 2009
  4. Marshall DA and Hux M.  Design and analysis issues for economic analysis alongside clinical trials. Medical Care 2009; 47(7) Suppl 1: S14–S20.
  5. Ikediobi ON, Shin J, Nussbaum B, Phillips KA, Walsh J, Ladabaum U, Marshall D. Addressing the challenges of the clinical application of Pharmacogenetic testing. Clinical Pharmacology & Therapeutics, 2009;86(1):193-215.
  6. Ferrusi I, Marshall DA, Kulin NA, Leighl N, Phillips KA. Looking back at 10 years of trastuzumab therapy: What is the role of HER-2 testing?  A systematic review of health economic analyses. Personalized Medicine 2009;6:193-215.
  7. Gooch K, Smith D, Wasylak T, Faris P, Marshall DA, Khong H, Hibbert J, Parker R, Zernicke R, Beaupre L, Pearce T, Johnston B, and Frank D. The design and execution of a pragmatic randomized controlled trial to evaluate a new evidence based continuum of care for the delivery of primary hip and knee replacements: The Alberta Hip and Knee Replacement Pilot Project. International Journal of Health Technology Assessment 2009; 25;2: 113-123.
  8. Phillips KA, Marshall DA, Haas J, Elkin E, Liang S-Y, Hassett M, Ferrusi I, Brock JE and Van Bebber S.  Clinical Practice Patterns and Cost-Effectiveness of HER2 Testing Strategies in Breast Cancer Patients.  Cancer 2009; 115(22):5166-74.PMID: 19753618
  9. Phillips KA on behalf of the TRANSPERS Research Group. Closing the Evidence Gap in the Use of Emerging Testing Technologies in Clinical Practice. JAMA 2008: 300(21): 2522-24.
  10. Marshall DA, Johnson FR, Kulin NA, Ozdemir S, Walsh J, Marshall JK, van Bebber, S, Phillips KA. How do physician expectations of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated choice survey. Health Economics 2009;18(12)

 

Search for citations for Dr. Marshall on PubMed